GB20
/ Shenzhen Kexing Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 04, 2026
Recently, Kexing Biopharma (688136.SH) announced that its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has received a Notice of Approval for Drug Clinical Trials from China's National Medical Products Administration (NMPA), authorizing the initiation of clinical trials of GB20...for inflammatory bowel disease (IBD).
(FinancialContent)
New trial • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1